论文部分内容阅读
当前中国医药创新生态系统中还存在诸多薄弱环节。今后5-10年最大的瓶颈问题集中在临床研究、监管审批和支付环节。如果这些要素没有在今后五年得到显著改善,医药行业将有可能失去当前来之不易的良好创新势头在医药行业,“创新药”的话题一直颇为火热。2016年10月31日,4家医药行业协会共同推动的《构建可持续发展的中国医药创新生态系统》的研究(以下简称《研究》)发布了主要成果。该报告联合发布方包括中国医药企业管理协会、中国化学制药
There are still many weak links in the current Chinese pharmaceutical innovation ecosystem. The biggest bottleneck in 5-10 years will focus on clinical research, regulatory approval and payment. If these elements have not been significantly improved in the next five years, the pharmaceutical industry will likely lose the current momentum of good momentum of innovation. In the pharmaceutical industry, the topic of “innovative medicine” has been quite hot. On October 31, 2016, four major pharmaceutical industry associations jointly launched the “Building a Sustainable Chinese Medicine Innovation Ecosystem” (hereinafter referred to as the “Research”) and published the major achievements. The report co-publishers include China Pharmaceutical Enterprise Management Association, China Chemical Pharmaceuticals